The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Highlights
The global Opiate Antagonist market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Opiate Antagonist is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Opiate Antagonist is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The global market for Opiate Antagonist in Hospital is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of Opiate Antagonist include Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceuticals, Cardinal Health, Baxter Pharmaceutical, Adapt Pharmaceuticals, Dr. Reddy's Laboratories, GIV Repack and Intl Medication Systems, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, 0.4 mg/ml, which accounted for % of the global market of Opiate Antagonist in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Opiate Antagonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opiate Antagonist.
The Opiate Antagonist market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Opiate Antagonist market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Opiate Antagonist companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Some of the prominent players reviewed in the research report include:
- Pfizer
- Sun Pharmaceutical Industries
- Teva Pharmaceuticals
- Cardinal Health
- Baxter Pharmaceutical
- Adapt Pharmaceuticals
- Dr. Reddy's Laboratories
- GIV Repack
- Intl Medication Systems
- Kaleo Pharma
- Mylan Institutional
- Perrigo Pharmaceuticals
- AuroMedics Pharma
- Somerset Pharma
- Akorn
- Alkermes
Product Type Insights
Global markets are presented by Opiate Antagonist type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Opiate Antagonist are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Opiate Antagonist segment by Type
- 0.4 mg/ml
- 1 mg/ml
- 2 mg/ml
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Opiate Antagonist market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Opiate Antagonist market.
Opiate Antagonist Segment by Application
- Hospital
- Clinics
- Pharmacy
- Home
- Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
- Latin America (Mexico, Brazil, Rest of Latin America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Opiate Antagonist market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opiate Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Opiate Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Opiate Antagonist industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opiate Antagonist.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Opiate Antagonist companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Opiate Antagonist Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 0.4 mg/ml
1.2.3 1 mg/ml
1.2.4 2 mg/ml
1.3 Market by Application
1.3.1 Global Opiate Antagonist Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Pharmacy
1.3.5 Home
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Opiate Antagonist Market Perspective (2017-2028)
2.2 Opiate Antagonist Growth Trends by Region
2.2.1 Opiate Antagonist Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Opiate Antagonist Historic Market Size by Region (2017-2022)
2.2.3 Opiate Antagonist Forecasted Market Size by Region (2023-2028)
2.3 Opiate Antagonist Market Dynamics
2.3.1 Opiate Antagonist Industry Trends
2.3.2 Opiate Antagonist Market Drivers
2.3.3 Opiate Antagonist Market Challenges
2.3.4 Opiate Antagonist Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Opiate Antagonist Players by Revenue
3.1.1 Global Top Opiate Antagonist Players by Revenue (2017-2022)
3.1.2 Global Opiate Antagonist Revenue Market Share by Players (2017-2022)
3.2 Global Opiate Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Opiate Antagonist Revenue
3.4 Global Opiate Antagonist Market Concentration Ratio
3.4.1 Global Opiate Antagonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Opiate Antagonist Revenue in 2021
3.5 Opiate Antagonist Key Players Head office and Area Served
3.6 Key Players Opiate Antagonist Product Solution and Service
3.7 Date of Enter into Opiate Antagonist Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Opiate Antagonist Breakdown Data by Type
4.1 Global Opiate Antagonist Historic Market Size by Type (2017-2022)
4.2 Global Opiate Antagonist Forecasted Market Size by Type (2023-2028)
5 Opiate Antagonist Breakdown Data by Application
5.1 Global Opiate Antagonist Historic Market Size by Application (2017-2022)
5.2 Global Opiate Antagonist Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Opiate Antagonist Market Size (2017-2028)
6.2 North America Opiate Antagonist Market Size by Country (2017-2022)
6.3 North America Opiate Antagonist Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Opiate Antagonist Market Size (2017-2028)
7.2 Europe Opiate Antagonist Market Size by Country (2017-2022)
7.3 Europe Opiate Antagonist Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Opiate Antagonist Market Size (2017-2028)
8.2 Asia-Pacific Opiate Antagonist Market Size by Country (2017-2022)
8.3 Asia-Pacific Opiate Antagonist Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Opiate Antagonist Market Size (2017-2028)
9.2 Latin America Opiate Antagonist Market Size by Country (2017-2022)
9.3 Latin America Opiate Antagonist Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Opiate Antagonist Market Size (2017-2028)
10.2 Middle East & Africa Opiate Antagonist Market Size by Country (2017-2022)
10.3 Middle East & Africa Opiate Antagonist Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Opiate Antagonist Introduction
11.1.4 Pfizer Revenue in Opiate Antagonist Business (2017-2022)
11.1.5 Pfizer Recent Development
11.2 Sun Pharmaceutical Industries
11.2.1 Sun Pharmaceutical Industries Company Detail
11.2.2 Sun Pharmaceutical Industries Business Overview
11.2.3 Sun Pharmaceutical Industries Opiate Antagonist Introduction
11.2.4 Sun Pharmaceutical Industries Revenue in Opiate Antagonist Business (2017-2022)
11.2.5 Sun Pharmaceutical Industries Recent Development
11.3 Teva Pharmaceuticals
11.3.1 Teva Pharmaceuticals Company Detail
11.3.2 Teva Pharmaceuticals Business Overview
11.3.3 Teva Pharmaceuticals Opiate Antagonist Introduction
11.3.4 Teva Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022)
11.3.5 Teva Pharmaceuticals Recent Development
11.4 Cardinal Health
11.4.1 Cardinal Health Company Detail
11.4.2 Cardinal Health Business Overview
11.4.3 Cardinal Health Opiate Antagonist Introduction
11.4.4 Cardinal Health Revenue in Opiate Antagonist Business (2017-2022)
11.4.5 Cardinal Health Recent Development
11.5 Baxter Pharmaceutical
11.5.1 Baxter Pharmaceutical Company Detail
11.5.2 Baxter Pharmaceutical Business Overview
11.5.3 Baxter Pharmaceutical Opiate Antagonist Introduction
11.5.4 Baxter Pharmaceutical Revenue in Opiate Antagonist Business (2017-2022)
11.5.5 Baxter Pharmaceutical Recent Development
11.6 Adapt Pharmaceuticals
11.6.1 Adapt Pharmaceuticals Company Detail
11.6.2 Adapt Pharmaceuticals Business Overview
11.6.3 Adapt Pharmaceuticals Opiate Antagonist Introduction
11.6.4 Adapt Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022)
11.6.5 Adapt Pharmaceuticals Recent Development
11.7 Dr. Reddy's Laboratories
11.7.1 Dr. Reddy's Laboratories Company Detail
11.7.2 Dr. Reddy's Laboratories Business Overview
11.7.3 Dr. Reddy's Laboratories Opiate Antagonist Introduction
11.7.4 Dr. Reddy's Laboratories Revenue in Opiate Antagonist Business (2017-2022)
11.7.5 Dr. Reddy's Laboratories Recent Development
11.8 GIV Repack
11.8.1 GIV Repack Company Detail
11.8.2 GIV Repack Business Overview
11.8.3 GIV Repack Opiate Antagonist Introduction
11.8.4 GIV Repack Revenue in Opiate Antagonist Business (2017-2022)
11.8.5 GIV Repack Recent Development
11.9 Intl Medication Systems
11.9.1 Intl Medication Systems Company Detail
11.9.2 Intl Medication Systems Business Overview
11.9.3 Intl Medication Systems Opiate Antagonist Introduction
11.9.4 Intl Medication Systems Revenue in Opiate Antagonist Business (2017-2022)
11.9.5 Intl Medication Systems Recent Development
11.10 Kaleo Pharma
11.10.1 Kaleo Pharma Company Detail
11.10.2 Kaleo Pharma Business Overview
11.10.3 Kaleo Pharma Opiate Antagonist Introduction
11.10.4 Kaleo Pharma Revenue in Opiate Antagonist Business (2017-2022)
11.10.5 Kaleo Pharma Recent Development
11.11 Mylan Institutional
11.11.1 Mylan Institutional Company Detail
11.11.2 Mylan Institutional Business Overview
11.11.3 Mylan Institutional Opiate Antagonist Introduction
11.11.4 Mylan Institutional Revenue in Opiate Antagonist Business (2017-2022)
11.11.5 Mylan Institutional Recent Development
11.12 Perrigo Pharmaceuticals
11.12.1 Perrigo Pharmaceuticals Company Detail
11.12.2 Perrigo Pharmaceuticals Business Overview
11.12.3 Perrigo Pharmaceuticals Opiate Antagonist Introduction
11.12.4 Perrigo Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022)
11.12.5 Perrigo Pharmaceuticals Recent Development
11.13 AuroMedics Pharma
11.13.1 AuroMedics Pharma Company Detail
11.13.2 AuroMedics Pharma Business Overview
11.13.3 AuroMedics Pharma Opiate Antagonist Introduction
11.13.4 AuroMedics Pharma Revenue in Opiate Antagonist Business (2017-2022)
11.13.5 AuroMedics Pharma Recent Development
11.14 Somerset Pharma
11.14.1 Somerset Pharma Company Detail
11.14.2 Somerset Pharma Business Overview
11.14.3 Somerset Pharma Opiate Antagonist Introduction
11.14.4 Somerset Pharma Revenue in Opiate Antagonist Business (2017-2022)
11.14.5 Somerset Pharma Recent Development
11.15 Akorn
11.15.1 Akorn Company Detail
11.15.2 Akorn Business Overview
11.15.3 Akorn Opiate Antagonist Introduction
11.15.4 Akorn Revenue in Opiate Antagonist Business (2017-2022)
11.15.5 Akorn Recent Development
11.16 Alkermes
11.16.1 Alkermes Company Detail
11.16.2 Alkermes Business Overview
11.16.3 Alkermes Opiate Antagonist Introduction
11.16.4 Alkermes Revenue in Opiate Antagonist Business (2017-2022)
11.16.5 Alkermes Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Opiate Antagonist Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of 0.4 mg/ml
Table 3. Key Players of 1 mg/ml
Table 4. Key Players of 2 mg/ml
Table 5. Global Opiate Antagonist Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Opiate Antagonist Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Opiate Antagonist Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Opiate Antagonist Market Share by Region (2017-2022)
Table 9. Global Opiate Antagonist Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Opiate Antagonist Market Share by Region (2023-2028)
Table 11. Opiate Antagonist Market Trends
Table 12. Opiate Antagonist Market Drivers
Table 13. Opiate Antagonist Market Challenges
Table 14. Opiate Antagonist Market Restraints
Table 15. Global Opiate Antagonist Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Opiate Antagonist Market Share by Players (2017-2022)
Table 17. Global Top Opiate Antagonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opiate Antagonist as of 2021)
Table 18. Ranking of Global Top Opiate Antagonist Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Opiate Antagonist Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Opiate Antagonist Product Solution and Service
Table 22. Date of Enter into Opiate Antagonist Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Opiate Antagonist Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Opiate Antagonist Revenue Market Share by Type (2017-2022)
Table 26. Global Opiate Antagonist Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Opiate Antagonist Revenue Market Share by Type (2023-2028)
Table 28. Global Opiate Antagonist Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Opiate Antagonist Revenue Market Share by Application (2017-2022)
Table 30. Global Opiate Antagonist Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Opiate Antagonist Revenue Market Share by Application (2023-2028)
Table 32. North America Opiate Antagonist Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Opiate Antagonist Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Opiate Antagonist Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Opiate Antagonist Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Opiate Antagonist Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Opiate Antagonist Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Opiate Antagonist Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Opiate Antagonist Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Opiate Antagonist Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Opiate Antagonist Market Size by Country (2023-2028) & (US$ Million)
Table 42. Pfizer Company Detail
Table 43. Pfizer Business Overview
Table 44. Pfizer Opiate Antagonist Product
Table 45. Pfizer Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 46. Pfizer Recent Development
Table 47. Sun Pharmaceutical Industries Company Detail
Table 48. Sun Pharmaceutical Industries Business Overview
Table 49. Sun Pharmaceutical Industries Opiate Antagonist Product
Table 50. Sun Pharmaceutical Industries Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 51. Sun Pharmaceutical Industries Recent Development
Table 52. Teva Pharmaceuticals Company Detail
Table 53. Teva Pharmaceuticals Business Overview
Table 54. Teva Pharmaceuticals Opiate Antagonist Product
Table 55. Teva Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 56. Teva Pharmaceuticals Recent Development
Table 57. Cardinal Health Company Detail
Table 58. Cardinal Health Business Overview
Table 59. Cardinal Health Opiate Antagonist Product
Table 60. Cardinal Health Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 61. Cardinal Health Recent Development
Table 62. Baxter Pharmaceutical Company Detail
Table 63. Baxter Pharmaceutical Business Overview
Table 64. Baxter Pharmaceutical Opiate Antagonist Product
Table 65. Baxter Pharmaceutical Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 66. Baxter Pharmaceutical Recent Development
Table 67. Adapt Pharmaceuticals Company Detail
Table 68. Adapt Pharmaceuticals Business Overview
Table 69. Adapt Pharmaceuticals Opiate Antagonist Product
Table 70. Adapt Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 71. Adapt Pharmaceuticals Recent Development
Table 72. Dr. Reddy's Laboratories Company Detail
Table 73. Dr. Reddy's Laboratories Business Overview
Table 74. Dr. Reddy's Laboratories Opiate Antagonist Product
Table 75. Dr. Reddy's Laboratories Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 76. Dr. Reddy's Laboratories Recent Development
Table 77. GIV Repack Company Detail
Table 78. GIV Repack Business Overview
Table 79. GIV Repack Opiate Antagonist Product
Table 80. GIV Repack Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 81. GIV Repack Recent Development
Table 82. Intl Medication Systems Company Detail
Table 83. Intl Medication Systems Business Overview
Table 84. Intl Medication Systems Opiate Antagonist Product
Table 85. Intl Medication Systems Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 86. Intl Medication Systems Recent Development
Table 87. Kaleo Pharma Company Detail
Table 88. Kaleo Pharma Business Overview
Table 89. Kaleo Pharma Opiate Antagonist Product
Table 90. Kaleo Pharma Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 91. Kaleo Pharma Recent Development
Table 92. Mylan Institutional Company Detail
Table 93. Mylan Institutional Business Overview
Table 94. Mylan Institutional Opiate AntagonistProduct
Table 95. Mylan Institutional Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 96. Mylan Institutional Recent Development
Table 97. Perrigo Pharmaceuticals Company Detail
Table 98. Perrigo Pharmaceuticals Business Overview
Table 99. Perrigo Pharmaceuticals Opiate AntagonistProduct
Table 100. Perrigo Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 101. Perrigo Pharmaceuticals Recent Development
Table 102. AuroMedics Pharma Company Detail
Table 103. AuroMedics Pharma Business Overview
Table 104. AuroMedics Pharma Opiate AntagonistProduct
Table 105. AuroMedics Pharma Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 106. AuroMedics Pharma Recent Development
Table 107. Somerset Pharma Company Detail
Table 108. Somerset Pharma Business Overview
Table 109. Somerset Pharma Opiate AntagonistProduct
Table 110. Somerset Pharma Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 111. Somerset Pharma Recent Development
Table 112. Akorn Company Detail
Table 113. Akorn Business Overview
Table 114. Akorn Opiate AntagonistProduct
Table 115. Akorn Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 116. Akorn Recent Development
Table 117. Alkermes Company Detail
Table 118. Alkermes Business Overview
Table 119. Alkermes Opiate AntagonistProduct
Table 120. Alkermes Revenue in Opiate Antagonist Business (2017-2022) & (US$ Million)
Table 121. Alkermes Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Opiate Antagonist Market Share by Type: 2021 VS 2028
Figure 2. 0.4 mg/ml Features
Figure 3. 1 mg/ml Features
Figure 4. 2 mg/ml Features
Figure 5. Global Opiate Antagonist Market Share by Application in 2021 & 2028
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Pharmacy Case Studies
Figure 9. Home Case Studies
Figure 10. Others Case Studies
Figure 11. Opiate Antagonist Report Years Considered
Figure 12. Global Opiate Antagonist Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Opiate Antagonist Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Opiate Antagonist Market Share by Region: 2021 VS 2028
Figure 15. Global Opiate Antagonist Market Share by Players in 2021
Figure 16. Global Top Opiate Antagonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opiate Antagonist as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Opiate Antagonist Revenue in 2021
Figure 18. North America Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. North America Opiate Antagonist Market Share by Country (2017-2028)
Figure 20. United States Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Opiate Antagonist Market Share by Country (2017-2028)
Figure 24. Germany Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. France Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. U.K. Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Italy Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Russia Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Nordic Countries Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Opiate Antagonist Market Share by Region (2017-2028)
Figure 32. China Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Japan Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. South Korea Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Southeast Asia Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. India Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Australia Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Latin America Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Latin America Opiate Antagonist Market Share by Country (2017-2028)
Figure 40. Mexico Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Brazil Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Middle East & Africa Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Middle East & Africa Opiate Antagonist Market Share by Country (2017-2028)
Figure 44. Turkey Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Saudi Arabia Opiate Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Pfizer Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 47. Sun Pharmaceutical Industries Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 48. Teva Pharmaceuticals Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 49. Cardinal Health Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 50. Baxter Pharmaceutical Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 51. Adapt Pharmaceuticals Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 52. Dr. Reddy's Laboratories Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 53. GIV Repack Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 54. Intl Medication Systems Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 55. Kaleo Pharma Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 56. Mylan Institutional Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 57. Perrigo Pharmaceuticals Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 58. AuroMedics Pharma Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 59. Somerset Pharma Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 60. Akorn Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 61. Alkermes Revenue Growth Rate in Opiate Antagonist Business (2017-2022)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
